文献速递白血病造血干细胞移植与细胞治疗

靶向细胞膜HDM2:急性髓系白血病的新型治疗策略

Targeting cell membrane HDM2: A novel therapeutic approach for acute myeloid leukemia.
PubMed 文献 · Leukemia · 2019-07-23

本文报道膜HDM2(mHDM2)特异性表达于人和小鼠AML原始细胞(含LSC富集亚群),而不表达于正常造血干细胞;mHDM2水平较高与白血病起始能力、静息状态及化疗耐药相关。合成肽PNC-27结合mHDM2并增强其与E-钙黏蛋白的相互作用,导致E-钙黏蛋白泛素化降解、膜损伤及AML原始细胞坏死性死亡。体内实验中PNC-27显著杀伤AML「bulk」原始细胞和LSC,同时不损伤正常HSC活性。

要点

  • mHDM2特异性表达于人和小鼠AML原始细胞(含LSC富集亚群),正常HSC不表达。
  • AML原始细胞mHDM2水平较高与白血病起始能力、静息及化疗耐药相关。
  • PNC-27结合mHDM2后经E-钙黏蛋白泛素化降解致AML细胞坏死性死亡,体内保留正常HSC活性。

核心结论

  • mHDM2是新的独特治疗靶点,PNC-27靶向mHDM2选择性杀伤AML细胞(含LSC),造血毒性最小。

研究设计与样本

  • 实验室与动物模型研究:检测人和小鼠AML原始细胞及正常HSC的mHDM2表达,并在人和鼠AML模型中行PNC-27体内外实验及原代、二次移植实验。

主要发现

  • mHDM2仅表达于人和小鼠AML原始细胞(含LSC富集亚群),不表达于正常HSC。
  • AML原始细胞mHDM2水平较高与白血病起始能力、静息状态和化疗耐药相关。
  • PNC-27结合mHDM2并增强mHDM2与E-钙黏蛋白相互作用,E-钙黏蛋白泛素化降解导致膜损伤及AML原始细胞坏死性死亡。
  • 体内PNC-27在原代和二次移植实验(人和鼠AML模型)中显著杀伤AML「bulk」原始细胞和LSC。
  • PNC-27在野生型小鼠原代和二次骨髓移植实验中不损伤正常HSC活性。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The E3 ligase human double minute 2 (HDM2) regulates the activity of the tumor suppressor protein p53. A p53-independent HDM2 expression has been reported on the membrane of cancer cells but not on that of normal cells. Herein, we first showed that membrane HDM2 (mHDM2) is exclusively expressed on human and mouse AML blasts, including leukemia stem cell (LSC)-enriched subpopulations, but not on normal hematopoietic stem cells (HSCs). Higher mHDM2 levels in AML blasts were associated with leukemia-initiating capacity, quiescence, and chemoresistance. We also showed that a synthetic peptide PNC-27 binds to mHDM2 and enhances the interaction of mHDM2 and E-cadherin on the cell membrane; in turn, E-cadherin ubiquitination and degradation lead to membrane damage and cell death of AML blasts by necrobiosis. PNC-27 treatment in vivo resulted in a significant killing of both AML "bulk" blasts and LSCs, as demonstrated respectively in primary and secondary transplant experiments, using both human and murine AML models. Notably, PNC-27 spares normal HSC activity, as demonstrated in primary and secondary BM transplant experiments of wild-type mice. We concluded that mHDM2 represents a novel and unique therapeutic target, and targeting mHDM2 using PNC-27 selectively kills AML cells, including LSCs, with minimal off-target hematopoietic toxicity.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Wang H, Zhao D, Nguyen LX, et al. Targeting cell membrane HDM2: A novel therapeutic approach for acute myeloid leukemia. Leukemia. 2019. PMID: 31337857. doi:10.1038/s41375-019-0522-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。